Loading…
Chinese pharma group combining generics and APIs with an overseas biologics unit that won FDA approval for a neutropenia drug.
Chinese pharma group combining generics and APIs with an overseas biologics unit that won FDA approval for a neutropenia drug.
Splits between generics and ingredients sold in volume and a long-acting biologic, Ryzneuta, which US partner Acrotech Biopharma sells after FDA approval in 2023, so licensing payments and royalties may become the higher-value stream.
In one line: A generics maker with one Amgen-style biologic win.
Moat: narrow (IP / patents). Rare Chinese-originated biologic with US FDA approval and an outside licensing partner.
Headquarters: Hefei, China · Employees: 4,221
Size Yifan Pharmaceutical (002019.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.72B, the 1438th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.60 on 6 Nov 2026.
Performance Over six months the shares fell 14.1%, against -4.8% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue fell 5.1% over the last twelve months (peer median +10.7%); the operating margin is 8.2% (peer median 15.2%).
Valuation It trades at 27.8× forward earnings against a peer median of 17.1× (6th most expensive of 16).
Capital Return on invested capital runs 2.2 points below its cost of capital (7.0% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.93B | CN¥5.11B | CN¥5.13B | CN¥4.04B | CN¥3.82B |
| Revenue growth | — | 0% | +27% | +6% | — |
| Gross profit | CN¥2.51B | CN¥2.32B | CN¥2.35B | CN¥1.85B | CN¥1.78B |
| EBITDA | n/a | CN¥804M | CN¥735M | CN¥289M | CN¥408M |
| Net income | CN¥311M | CN¥402M | CN¥386M | -CN¥551M | CN¥191M |
| Free cash flow | -CN¥27.3M | -CN¥101M | CN¥15.2M | -CN¥151M | -CN¥68.2M |
| Capital expenditure | CN¥593M | CN¥559M | CN¥628M | CN¥504M | CN¥542M |
| Total debt | CN¥2.96B | CN¥2.36B | CN¥2.29B | CN¥2.00B | CN¥2.18B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yifan Pharmaceutical 002019.SZ | $1.72B | -14% | -5% | 8% | 27.8× | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 18.9× | 1.8% |
| Kyowa Kirin 4151.T | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002019.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | -0.1% | 10th highest of 21 |
| 6-month return | -14.1% | -4.8% | 5th lowest of 20 |
| Distance from 52-week high | -34.8% | -27.9% | 9th lowest of 21 |
| Revenue growth (TTM) | -5.1% | +10.7% | 4th lowest of 19 |
| Operating margin | 8.2% | 15.2% | 5th lowest of 19 |
| Forward P/E | 27.8× | 17.1× | 6th most expensive of 16 |
| ROIC minus cost of capital | -2.2 pp | +1.5 pp | 5th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 16.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 27.9× | 39.6% | +359.6% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | n/a | -4.1% | +0.2% |